Cancer Research on Prevention and Treatment    2022, Vol. 49 Issue (06) : 528-534     DOI: 10.3971/j.issn.1000-8578.2022.21.1337
|
Current Progress in Treatment of Glioma
ZHANG Yu1, HE Kunyu2, FENG Shiyu2
1. Department of Neurosurgery, School of Clinical Medicine, Hebei University, Baoding 071000, China; 2. Department of Neurosurgery, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
Download: PDF(3555 KB)   ( 126 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Although the diagnosis of glioma is constantly changing with the update of WHO diagnostic guidelines, the current treatment methods are still mainly surgical treatment, supplemented by radiotherapy and chemotherapy. It is a pity that the treatment effect of high-grade glioma is still unsatisfactory. How to improve the prognosis of patients is the key problem in the field of medical exploration of glioma. It is gratifying that many new ideas and methods have emerged in the diagnosis and treatment of glioma, in which some trials represented by tumor treating fields have achieved good results in clinical research, moreover, the fields of immunotherapy and targeted therapy have developed too. This paper aims to share and explore these new methods and summarize the progress of diagnosis and treatment of glioma.
Keywords Glioma      Molecular pathology      Targeted therapy      Immunotherapy      Tumor treating fields     
ZTFLH:  R739.41  
Issue Date: 15 June 2022
 Cite this article:   
ZHANG Yu,HE Kunyu,FENG Shiyu. Current Progress in Treatment of Glioma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 528-534.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.21.1337
http://www.zlfzyj.com/EN/Y2022/V49/I06/528
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
ZHANG Yu
HE Kunyu
FENG Shiyu
[1] Rouzbeh B, Christian H. The new WHO 2016 classification
of brain tumors-what neurosurgeons need to know[J]. Acta
Neurochir(Wien), 2017, 159(3): 403-418.
[2] 申楠茜, 张佳璇, 甘桐嘉. 2021年WHO中枢神经系统肿瘤分类
概述[J]. 放射学实践, 2021, 36(7): 818-831. [Shen NX, Zhang
JX, Gan TJ, et al. The 2021 WHO Classification of Tumors of the
Central Nerv-ous System: a summary[J]. Fang She Xue Shi jian,
2021, 36(7): 818-831.]
[3] 国家卫生健康委员会医政医管局. 脑胶质瘤诊疗规范(2018
年版)[J]. 中华神经外科杂志, 2019, 35(3): 217-239. [Medical
administration of National Health Commission. Standard for
diagnosis and treatment of glioma(2018)[J]. Zhonghua Shen Jing
Wai Ke Za Zhi, 2019, 35(3): 217-239.]
[4] Jiang T, Mao Y, Ma W, et al. CGCG clinical practice guidelines for
the management of adult diffuse gliomas[J]. Cancer Lett, 2016,
375(2): 263-273.
[5] 樊星, 刘幸, 柴睿超, 等. 2020版美国国立综合癌症网络脑胶
质瘤临床实践指南解读[J]. 中华神经外科杂志, 2021, 37(6):
541-545. [Fan X, Liu X, Chai RC, et al. Interpretation of the 2020
National Comprehensive Cancer Network glioma clinical practice
guide[J]. Zhonghua Shen Jing Wai Ke Za Zhi, 2021, 37(6):
541-545.]
[6] Pace A, Dirven L, Koekkoek JAF, et al. European Association for
Neuro-Oncology (EANO) guidelines for palliative care in adults
with glioma[J]. Lancet Oncol, 2017, 18(6): e330-e340.
[7] Sanai N, Polley MY, McDermott MW, et al. An extent of resection
threshold for newly diagnosed glioblastomas[J]. J Neurosurg,
2011 , 11 5(1): 3-8.
[8] Molinaro AM, Hervey-Jumper S, Morshed RA, et al. Association
of Maximal Extent of Resection of Contrast-Enhanced and Non-
Contrast-Enhanced Tumor With Survival Within Molecular
Subgroups of Patients With Newly Diagnosed Glioblastoma[J].
JAMA Oncol, 2020, 6(4): 495-503.
[9] Englot DJ, Han SJ, Berger MS, et al. Extent of surgical resection
predicts seizure freedom in low-grade temporal lobe brain
tumors[J]. Neurosurgery, 2012, 70(4): 921-928.
[10] Traylor JI, Patel R, Muir M, et al. Laser Interstitial Thermal
Therapy for Glioblastoma: A Single-Center Experience. World
Neurosurg[J]. World Neurosurg, 2021, 149: e244-e252.
[11 ] Zhang X, Chen Y, Yao J, et al. β-elemene combined with
temozolomide in treatment of brain glioma[J]. Biochem Biophys
Rep, 2021, 28: 1011 44.
[12] Herrlinger U, Tzaridis T, Mack F, et al. Lomustine-temozolomide
combination therapy versus standard temozolomide therapy in
patients with newly diagnosed glioblastoma with methylated
MGMT promoter (CeTeG/NOA-09): a randomised, open-label,
phase 3 trial[J]. Lancet, 2019, 393(10172): 678-688.
[13] Beccaria K, Canney M, Bouchoux G, et al. Blood-brain barrier
disruption with low-intensity pulsed ultrasound for the treatment
of pediatric brain tumors: a review and perspectives[J]. Neurosurg
Focus, 2020, 48(1): E10.
[14] Breen WG, Anderson SK, Carrero XW, et al. Final report from
Intergroup NCCTG 86-72-51 (Alliance): a phase Ⅲ randomized
clinical trial of high-dose versus low-dose radiation for adult lowgrade
glioma[J]. Neuro Oncol, 2020, 22(6): 830-837.
[15] Bell EH, Zhang P, Fisher BJ, et al. Association of MGMT
Promoter Methylation Status With Survival Outcomes in
Patients With High-Risk Glioma Treated With Radiotherapy and

Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial[J].

JAMA Oncol, 2018, 4(10): 1405-1409.

[16] Brown PD, Chung C, Liu DD, et al. A prospective phaseⅡ
randomized trial of proton radiotherapy vs intensity-modulated
radiotherapy for patients with newly diagnosed glioblastoma[J].
Neuro Oncol, 2021, 23(8): 1337-1347.
[17] Fleischmann DF, Sch?n R, Corradini S, et al. Multifocal highgrade
glioma radiotherapy safety and efficacy[J]. Radiat Oncol,
2021, 16(1): 165.
[18] Kirson ED, Dbaly V, Tovarys F, et al. Alternating electric fields
arrest cell proliferation in animal tumor models and human
brain tumors[J]. Proc Natl Acad Sci U S A, 2007, 1 04(24):
10152-10157.
[19] Stupp R, Taillibert S, Kanner A, et al. Effect of Tumor-Treating
Fields Plus Maintenance Temozolomide vs Maintenance
Temozolomide Alone on Survival in Patients With Glioblastoma:
A Randomized Clinical Trial[J]. JAMA, 2017, 318(23):
2306-2316.
[20] Mrugala MM, Engelhard HH, Tran DD, et al. Clinical practice
experience with NovoTTF-100A? system for glioblastoma: The
Patient Registry Dataset (PRiDe)[J]. Semin Oncol, 2014, 41 Suppl
6: S4-S13.
[21] Guberina N, P?ttgen C, Kebir S, et al. Combined radiotherapy
and concurrent tumor treating fields (TTFields) for glioblastoma:
Dosimetric consequences on non-coplanar IMRT as initial results
from a phaseⅠ trial[J]. Radiat Oncol, 2020, 15(1): 83.
[22] Miller R, Song A, Ali A, et al. CTNI-21. Scalp sparing radiation
with concurrent temozolomide and tumor treatment fields (spare)
for patients with newly diagnosed glioblastoma[J]. Neuro-Oncol,
22, ii46-ii47. https://academic.oup.com/neuro-oncology/article/22/
Supplement_2/ii46/5960637?login=false
[23] Dono A, Mitra S, Shah M, et al. PTEN mutations predict benefit
from tumor treating fields (TTFields) therapy in patients with
recurrent glioblastoma[J]. J Neurooncol, 2021, 153(1): 153-160.
[24] Shiao Pei S. Weathers, Carlos Kamiya Matsuoka, Rebecca A.
Harrison, et al. PhaseⅠ/Ⅱ study to evaluate the safety and
clinical efficacy of atezolizumab (atezo; aPDL1) in combination
with temozolomide (TMZ) and radiation in patients with newly
diagnosed glioblastoma (GBM)[J]. J Clin Oncol, 2020, 38,
2511 -2511 . https://ascopubs.org/doi/10.1200/JCO.2020.38.15_sup
pl.2511 [25] Sampson JH, Achrol A, Aghi MK, et al. MDNA55 survival
in recurrent glioblastoma (rGBM) patients expressing the
interleukin-4 receptor (IL4R) as compared to a matched synthetic
control[J]. J Clin Oncol, 2020, 38, 2513-2513.

[26] Dai B, Qi N, Li J, et al. Temozolomide combined with PD-1 Antibody

 therapy for mouse orthotopic glioma model[J]. Biochem Biophys Res Commun, 2018, 501(4): 871-876.

[27] Reardon DA, Brem S, Desai AS, et al. INO-5401 and INO-9012
delivered intramuscularly (IM) with electroporation (EP) in
combination with cemiplimab (REGN2810) in newly diagnosed
glioblastoma (GBM): Interim results[J]. J Clin Oncol, 2020,
38(15_suppl): 2514.
[28] Cloughesy TF, Mochizuki AY, Orpilla JR, et al. Neoadjuvant
anti-PD-1 immunotherapy promotes a survival benefit with
intratumoral and systemic immune responses in recurrent
glioblastoma[J]. Nat Med, 2019, 25(3): 477-486.
[29] Kurz SC, Cabrera LP, Hastie D, et al. PD-1 inhibition has only
limited clinical benefit in patients with recurrent high-grade
glioma[J]. Neurology, 2018, 91(14): e1355-e1359.
[30] Keskin DB, Anandappa AJ, Sun J, et al. Neoantigen vaccine
generates intratumoral T cell responses in phaseⅠb glioblastoma
trial[J]. Nature, 2019, 565(7738): 234-239.
[31] Hilf N, Kuttruff-Coqui S, Frenzel K, et al. Actively personalized
vaccination trial for newly diagnosed glioblastoma[J]. Nature,
2019, 565(7738): 240-245.
[32] Platten M, Bunse L, Wick A, et al. A vaccine targeting mutant
IDH1 in newly diagnosed glioma[J]. Nature, 2021, 592(7854):
463-468.
[33] Detti B, Scoccianti S, Teriaca MA, et al. Bevacizumab in recurrent
high-grade glioma: a single institution retrospective analysis on
92 patients[J]. Radiol Med, 2021, 126(9): 1249-1254.
[34] Lombardi G, De Salvo GL, Brandes AA, et al. Regorafenib
compared with lomustine in patients with relapsed glioblastoma
(REGOMA): a multicentre, open-label, randomised, controlled,
phase 2 trial[J]. Lancet Oncol, 2019, 20(1): 11 0-11 9.
[35] Subbiah V, Puzanov I, Blay JY, et al. Pan-Cancer Efficacy of
Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers[J].
Cancer Discov, 2020, 10(5): 657-663.
[36] Wen PY, De Groot JF, Battiste JD, et al. Escalation portion of
phaseⅡstudy to evaluate the safety, pharmacokinetics, and clinical
activity of the PI3K/mTOR inhibitor paxalisib (GDC-0084) in
glioblastoma (GBM) with unmethylated O6-methylguaninemethyltransferase
(MGMT) promotor status[J]. J Clin Oncol,
2020, 38(15_suppl): 2550.
[37] Doz F, van Tilburg CM, Geoerger B, et al. Efficacy and safety
of larotrectinib in TRK fusion-positive primary central nervous
system tumors[J]. Neuro Oncol, 2021, noab274.
[38] Ducray F, POLA network, Sanson M, et al. KS02.4.A olaparib in
recurrent idh-mutant high-grade glioma (OLAGLI)[J]. Neuro-
Oncol, 23, ii4.
[39] Sanphanya K, Wattanapitayakul SK, Phowichit S, et al. Novel
VEGFR-2 kinase inhibitors identified by the back-to-front
approach[J]. Bioorg Med Chem Lett, 2013, 23(10): 2962-2967.
[40] Lai Shuzhen, Chen Yuanyuan. Anlotinib combined with stupp
regimen in treating patients with newly diagnosed glioblastoma
multiforme: a phase ii pilot study[J]. Neuro-Oncol, 22, ii52.
[41] Cao Y, Xu L, Tang X, et al. 358P Anlotinib plus temozolomide
for recurrent glioma: A single-center, retrospective study of 30
cases[J]. Ann Oncol, 2021, 32(S5): S522-S522.
[42] 吴广银, 赵瑞莹, 李良, 等. 安罗替尼对胶质瘤放疗的增敏作用
及其机制[J]. 中华实验外科杂志, 2021, 38(3): 468-471. [Wu
GY, Zhao RY, Li L, et al. Observation and mechanism exploration
of the radiotherapy sensitization effect of antinib on glioma[J].
Zhonghua Shi Yan Wai Ke Za Zhi, 2021, 38(3): 468-471.]
[43] Lang FF, Conrad C, Gomez-Manzano C, et al. Phase Ⅰ Study of
DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication
and Immunotherapeutic Effects in Recurrent Malignant Glioma[J].
J Clin Oncol, 2018, 36(14): 1419-1427.

[44] Firedman GK, Johnston JM, Bag AK, et al. Oncolytic HSV-1 G207

 Immunovirotherapy for Pediatric High-Grade Gliomas[J]. N Engl J Med, 2021, 384(17): 1613-1622.

[45] Desjardins A, Gromeier M, Herndon JE 2nd, et al. Recurrent
Glioblastoma Treated with Recombinant Poliovirus[J]. N Engl J
Med, 2018, 379(2): 150-161.
Related articles from Frontiers Journals
[1] YANG Junyuan, CAI Hongbing. Countermeasures and Mechanisms of Drug Resistance in Immunotherapy for Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 886-892.
[2] YIN Zhucheng, LIANG Xinjun. Research Progress on Combined Immunotherapy for Microsatellite Stable Colorectal Cancer#br#[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 977-981.
[3] CAO Guangwen. Theoretical Update of Cancer Evo-Dev and Its Role in Targeted Immunotherapy for Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 747-755.
[4] KANG Yikun, YUAN Peng. Advances in Treatment of Triple Negative Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 812-819.
[5] YIN Zhucheng, LIANG Xinjun. Research Progress on Hyperthermia and Anti-Tumor Immunity[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 827-831.
[6] XIA Siyu, ZHAO Zitong, LI Li. Correlation Between STK11 Gene Mutation and Immunotherapy of Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 850-854.
[7] CHEN Yarui, WANG Jiangtao, GUAN Quanlin, JI Wei, JIAO Fuzhi. Research Progress of Antibody-drug Conjugates in Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 855-860.
[8] CHEN Weichang, SHI Tongguo, ZHU Jinghan, SUN Linqing, LI Juntao. Progress on Immunotherapy of Gastrointestinal Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 639-643.
[9] JIN Tongtong, ZHOU Chuan, WANG Chao, DA Zijian, ZHOU Fenghai, . Research Hotspots and Frontiers of Immunotherapy for Prostate Cancer: A Visual Analysis[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 667-674.
[10] WU Wei, JING Doudou, CAO Li, PU Feifei, SHAO Zengwu. Current Status and Prospects of Immunotherapy for Osteosarcoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 721-726.
[11] CHEN Bojin, HU Xingyi, ZHAO Jingwen, ZHENG Aihong. Current Status of Immunotherapy in Neoadjuvant Therapy for Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 727-732.
[12] ZHANG Jianning, LIU Congwei. Progress of Novel Treatment Options for Glioma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 505-513.
[13] JIA Muyuan, LI Ze, LIU Yuyang, LIU Jialin, ZHENG Xiaoque, BAI Yunjuan, CHEN Ling. Progress in Multidisciplinary Diagnosis and Treatment of Familial Brain Tumors[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 514-521.
[14] SUN Junzhao, CHENG Gang, ZHANG Jianning. Advances in Treatment of Brain Metastasis from Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 522-527.
[15] LI Yuxin, JIN Feng, . Immune Checkpoint PD-1-based Mechanisms of Tumor Immune Resistance and Strategies for Re-treatment After Drug Resistance[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 546-551.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed